SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE
QUARTERLY PERIOD ENDED

September 30, 2005

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE
TRANSITION PERIOD FROM ______ TO ______

Commission file number 0-19711

The Spectranetics Corporation

(Exact name of Registrant as specified in its charter)

Delaware	84-0997049
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

96 Talamine Court
Colorado Springs, Colorado 80907
(719) 633-8333
(Address of principal executive offices and telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ  No o

Indicate by check mark whether the Registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act ). Yes þ  No o

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes o  No þ

As of November 7, 2005 there were 26,177,714 outstanding shares of Common Stock.

TABLE OF CONTENTS

Part I—FINANCIAL INFORMATION
	Item 1. Financial Statements
	Item 1. Notes to Financial Statements
	Item 2. Management’s Discussion and Analysis of Results of Operations and Financial Condition
	Item 3. Quantitative and Qualitative Disclosures About Market Risk
	Item 4. Controls and Procedures
Part II—OTHER INFORMATION
	Item 1. Legal Proceedings
	Items 2-5. Not applicable
	Item 6. Exhibits
SIGNATURES
Employment Letter Agreement - Will McGuire
Rule 13(a)-14(a)/15d-14(a) Certification
Rule 13(a)-14(a)/15d-14(a) Certification
Section 1350 Certification
Section 1350 Certification

Part I—FINANCIAL INFORMATION

Item 1. Financial Statements

THE SPECTRANETICS CORPORATION AND SUBSIDIARY
Condensed Consolidated Balance Sheets
(In Thousands, Except Share Amounts)

	September 30,			December 31,
	2005			2004
	(unaudited)
Assets:
Current assets:
Cash and cash equivalents	$	5,323		$	4,004
Investment securities available for sale		8,505			9,963
Trade accounts receivable, net of allowances of $327 and $239, respectively		7,416			6,456
Inventories, net		3,462			1,782
Deferred income taxes, net		32			88
Prepaid expenses and other current assets		817			835
Total current assets		25,555			23,128
Property, plant and equipment, net of accumulated depreciation of $9,908 and $10,183, respectively		7,182			4,362
Long-term investment securities available for sale		2,972			3,443
Long-term deferred income taxes, net		1,011			1,527
Goodwill, net		308			308
Other intangible assets, net		70			124
Other assets		113			146
Total Assets	$	37,211		$	33,038
Liabilities and Shareholders’ Equity:
Current liabilities:
Accounts payable and accrued liabilities	$	8,392		$	7,499
Deferred revenue		2,158			1,967
Total current liabilities		10,550			9,466
Deferred revenue, noncurrent		22			56
Other long-term liabilities		18			27
Total liabilities		10,590			9,549
Commitments and contingencies		—			—
Shareholders’ Equity:
Preferred stock, $.001 par value; authorized 5,000,000 shares; none issued		—			—
Common stock, $.001 par value; authorized 60,000,000 shares; issued and outstanding 26,150,938 and 25,377,939 shares, respectively		26			25
Additional paid-in capital		99,321			96,823
Accumulated other comprehensive income (loss)		(140	)		50
Accumulated deficit		(72,586	)		(73,409	)
Total shareholders’ equity		26,621			23,489
Total Liabilities and Shareholders’ Equity	$	37,211		$	33,038

See accompanying unaudited notes to condensed consolidated financial statements.

Page 2

Item 1. Financial Statements (cont’d)

THE SPECTRANETICS CORPORATION AND SUBSIDIARY
Condensed Consolidated Statements of Operations and Comprehensive Income
(In Thousands, Except Share and Per Share Amounts)
(Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2005			2004			2005			2004
Revenue	$	11,230		$	8,934		$	30,928		$	25,378
Cost of revenue		2,643			2,123			7,458			6,416
Gross margin		8,587			6,811			23,470			18,962
Operating expenses:
Selling, general and administrative		6,128			4,817			17,394			14,146
Research, development and other technology		1,950			1,551			4,968			3,898
Total operating expenses		8,078			6,368			22,362			18,044
Operating income		509			443			1,108			918
Other income (expense):
Interest expense		(3	)		—			(8	)		—
Interest income		113			56			290			152
Other, net		4			1			8			8
Total other income		114			57			290			160
Income before income tax expense		623			500			1,398			1,078
Income tax expense		(117	)		(21	)		(575	)		(63	)
Net income	$	506		$	479		$	823		$	1,015
Other comprehensive income (loss):
Foreign currency translation		3			13			(165	)		(22	)
Unrealized gain (loss) on investment securities		(25	)		25			(25	)		(19	)
Comprehensive income	$	484		$	517		$	633		$	974
Net income per share — basic and diluted	$	0.02		$	0.02		$	0.03		$	0.04
Weighted average common shares outstanding:
Basic		26,070,324			25,266,882			25,851,908			24,990,864
Diluted		28,483,366			27,279,396			27,980,415			27,031,422

See accompanying unaudited notes to condensed consolidated financial statements.

Page 3

Item 1. Financial Statements (cont’d)

THE SPECTRANETICS CORPORATION AND SUBSIDIARY
Condensed Consolidated Statements of Cash Flows (In Thousands)
(Unaudited)

	Nine Months Ended September 30,
	2005			2004
Cash flows from operating activities:
Net income	$	823		$	1,015
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization		1,267			1,166
Fair value of options granted for consulting services		10			22
Deferred income taxes		572			—
Net change in operating assets and liabilities		(3,467	)		(2,096	)
Net cash provided by (used in) operating activities		(795	)		107
Cash flows from investing activities:
Purchase of land and building		(1,350	)		—
Other capital expenditures		(818	)		(351	)
Sales of investment securities		7,011			17,637
Purchases of investment securities		(5,107	)		(29,051	)
Net change in restricted cash		—			1,133
Net cash used in investing activities		(264	)		(10,632	)
Cash flows from financing activities:
Proceeds from sale of common stock		2,489			2,063
Net cash provided by financing activities		2,489			2,063
Effect of exchange rate changes on cash		(111	)		(25	)
Net increase (decrease) in cash and cash equivalents		1,319			(8,487	)
Cash and cash equivalents at beginning of period		4,004			11,281
Cash and cash equivalents at end of period	$	5,323		$	2,794
Supplemental disclosures of cash flow information —
Cash paid for taxes	$	20		$	131

See accompanying unaudited notes to condensed consolidated financial statements.

Page 4

Item 1. Notes to Financial Statements

(1) General

     We design, manufacture, market and distribute single-use medical devices used in minimally invasive surgical procedures within the vascular system in conjunction with our proprietary excimer laser system. Excimer laser technology delivers comparatively cool ultraviolet light in short, controlled energy pulses to ablate or remove blockages. Our excimer laser system includes the CVX-300® laser unit and various fiber-optic delivery devices, including disposable catheters and sheaths. Our excimer laser system is the only excimer laser system approved in the United States and Europe for use in multiple, minimally invasive cardiovascular applications. Our excimer laser system is used in complex atherectomy procedures to open clogged or obstructed arteries in the coronary and peripheral vascular system. It is also used to remove lead wires from patients with implanted pacemakers or cardioverter defibrillators, which are electronic devices that regulate the heartbeat. In April 2004, we received 510(k) clearance from the Food and Drug Administration (“FDA”) for our CliRpath® laser catheters which are indicated for use in the endovascular treatment of peripheral artery disease where total obstructions are not crossable with a guidewire.

     The accompanying condensed consolidated financial statements include the accounts of The Spectranetics Corporation, a Delaware corporation, and its wholly-owned subsidiary, Spectranetics International, B.V. (collectively, the Company). All intercompany balances and transactions have been eliminated in consolidation.

     We prepare our condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America. As such, management is required to make certain estimates, judgments and assumptions based upon the information available. These estimates and assumptions affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. Significant items subject to such estimates and assumptions include the carrying amount of property and equipment and intangible assets; valuation allowances for receivables, inventories and deferred income tax assets; and accrued warranty and royalty expenses. Actual results could differ from those estimates.

     The information included in the accompanying condensed consolidated interim financial statements is unaudited and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s latest Annual Report on Form 10-K. In the opinion of management, all adjustments necessary for a fair presentation of the assets, liabilities and results of operations for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the entire year.

(2) Stock-Based Compensation

     The Company accounts for its stock-based compensation plans for employees in accordance with the provisions of Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees (APB 25), and related interpretations. As such, compensation expense is recorded on the date of grant only if the current market price of the underlying stock exceeds the exercise price. No compensation cost has been recognized for stock option grants to employees in the accompanying financial statements as all options granted had an exercise price equal to or above the market value of the underlying common stock on the date of grant. Under FASB Statement No. 123, Accounting for Stock-Based Compensation (SFAS No. 123), and FASB Statement No. 148, Accounting for Stock-Based Compensation — Transition and Disclosure, an amendment of SFAS No. 123 (SFAS No. 148), entities are permitted to recognize as expense the fair value of all stock-based awards on the date of grant over the vesting period. Alternatively, SFAS No. 123, as

Page 5

amended, also allows entities to continue to apply the provisions of APB 25 and provide pro forma earnings (loss) and pro forma earnings (loss) per share disclosures for employee stock option grants as if the fair-value-based method defined in SFAS No. 123, as amended, had been applied. The Company has elected to continue to apply the provisions of APB 25 and provide the pro forma disclosures required by SFAS No. 123, as amended.

     The Company accounts for nonemployee stock-based awards in accordance with SFAS No. 123 and related interpretations.

     The following table illustrates the effect on net income and net income per share if the Company had applied the fair value recognition provisions of SFAS No. 123 to stock-based employee compensation for the three months and nine months ended September 30, 2005 and 2004 (in thousands, except per share amounts):

	Three months ended						Nine months ended
	September 30,						September 30,
	2005			2004			2005			2004
Net income, as reported	$	506		$	479		$	823		$	1,015
Deduct: Total stock-based employee compensation expense attributable to common stock options determined under fair value based method, net of tax		(363	)		(123	)		(693	)		(410	)
Pro forma net income	$	143		$	356		$	130		$	605
Income per share — basic, as reported	$	0.02		$	0.02		$	0.03		$	0.04
Income per share — diluted, as reported	$	0.02		$	0.02		$	0.03		$	0.04
Income per share — basic, pro forma	$	0.01		$	0.01		$	0.01		$	0.02
Income per share — diluted, pro forma	$	0.01		$	0.01		$	0.00		$	0.02

     The per share weighted-average fair value of stock options granted during the third quarter of 2005 and 2004 was $7.34 and $4.36, respectively, using the Black-Scholes option pricing model. The per share weighted-average fair value of stock options granted during the nine months ended September 30, 2005 and 2004 was $5.81 and $4.30, respectively, using the Black-Scholes option pricing model. The Company used the following weighted average assumptions in determining the fair value of options granted during the three months and nine months ended September 30, 2005 and 2004:

	Three months ended						Nine months ended
	September 30,						September 30,
	2005			2004			2005			2004
Expected life (years)		4.74			5.53			5.39			5.38
Risk-free interest rate		4.2	%		3.4	%		4.0	%		3.4	%
Expected volatility		162.5	%		116.6	%		158.1	%		118.0	%
Expected dividend yield	None			None			None			None

(3) Net Income Per Share

     The Company calculates net income per share under the provisions of Statement of Financial Accounting Standards No. 128, Earnings Per Share (SFAS 128). Under SFAS 128, basic earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding. Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. Diluted earnings per share are computed in a manner

Page 6

consistent with that of basic earnings per share while giving effect to all potentially dilutive common shares outstanding during the period using the treasury stock method.

     For the three months ended September 30, 2005 and September 30, 2004, 412,313 and 439,953 stock options, respectively, were excluded from the computation of diluted earnings per share due to their antidilutive effect. For the nine months ended September 30, 2005 and 2004, respectively, 700,538 and 676,748 stock options were excluded from the computation due to their antidilutive effect. A summary of the net income per share calculation is shown below (in thousands, except per share amounts):

	Three months ended				Nine months ended
	September 30,				September 30,
	2005		2004		2005		2004
Net income	$	506	$	479	$	823	$	1,015
Common shares outstanding:
Historical common shares outstanding at beginning of period		25,980		25,147		25,378		24,452
Weighted average common shares issued		90		120		474		539
Weighted average common shares outstanding — basic		26,070		25,267		25,852		24,991
Effect of dilution — stock options		2,413		2,012		2,128		2,040
Weighted average common shares outstanding — diluted		28,483		27,279		27,980		27,031
Net income per share — basic	$	0.02	$	0.02	$	0.03	$	0.04
Net income per share — diluted	$	0.02	$	0.02	$	0.03	$	0.04

(4) Inventories

     Inventories consist of the following (in thousands):

	September 30, 2005			December 31, 2004
Raw materials	$	889		$	439
Work in process		1,687			364
Finished goods		1,128			1,051
Less reserve for obsolescence and inventory variance		(242	)		(72	)
	$	3,462		$	1,782

Page 7

(5) Property, Plant and Equipment

     Property, plant and equipment consist of the following (in thousands):

	September 30,			December 31,
	2005			2004
Land	$	270		$	—
Building		1,084			—
Manufacturing equipment and computers		6,449			6,283
Leasehold improvements		661			1,014
Equipment held for rental or loan		8,445			7,064
Furniture and fixtures		181			184
Less: accumulated depreciation		(9,908	)		(10,183	)
	$	7,182		$	4,362

     On March 29, 2005, the Company acquired the building and land which houses its manufacturing facilities in Colorado for $1,350,000 in cash. The purchase price was allocated between land and building based on the relative fair value of the assets acquired.

     Property and equipment are recorded at cost. Repairs and maintenance costs are expensed as incurred. Equipment acquired under capital leases is recorded at the present value of minimum lease payments at the inception of the lease.

     Depreciation is calculated using the straight-line method over the estimated useful lives of the assets of three to five years for manufacturing equipment, computers, and furniture and fixtures. Equipment held for rental or loan is depreciated using the straight-line method over three to five years. Equipment acquired under capital leases and leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful life of the asset. The building is depreciated using the straight-line method over its remaining estimated useful life of 20 years.

(6) Deferred Revenue

     Deferred revenue was $2,180,000 and $2,023,000 at September 30, 2005 and December 31, 2004, respectively. These amounts primarily relate to payments in advance for various product maintenance contracts in which revenue is initially deferred and recognized over the life of the contract, which is generally one year, and to deferred revenue associated with service provided to our customers during the warranty period after the sale of equipment. Additional information relating to the deferral of revenue associated with the warranty provided upon sale of equipment is included in Footnote 9, “Revenue Recognition.”

(7) Segment and Geographic Reporting

     An operating segment is a component of an enterprise whose operating results are regularly reviewed by the enterprise’s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance. The primary performance measure used by management is net income or loss. The Company operates in one distinct line of business, which is the development, manufacture, marketing and distribution of a proprietary excimer laser system for the treatment of certain coronary and vascular conditions. The Company has identified two reportable geographic segments within this line of business: (1) U.S. Medical and (2) Europe Medical. U.S. Medical

Page 8

and Europe Medical offer the same products and services but operate in different geographic regions and have different distribution networks. Additional information regarding each reportable segment is shown below.

U.S. Medical

     Products offered by this reportable segment include an excimer laser unit (“equipment”), fiber-optic delivery devices (“disposables”), and the service of the excimer laser unit (“service”). The Company is subject to product approvals from the FDA. At September 30, 2005, FDA-approved products were used in multiple vascular procedures, including coronary and peripheral atherectomy as well as the removal of nonfunctioning leads from pacemakers and cardiac defibrillators. In April 2004, the Company received 510(k) clearance from the FDA to sell fiber-optic delivery devices for the treatment of patients suffering from total occlusions (blockages) not crossable with a guidewire in their leg arteries. This segment’s customers are primarily located in the United States; however, the geographic areas served by this segment also include Canada, Mexico, South America, the Pacific Rim and Australia.

     U.S. Medical is also corporate headquarters for the Company. Accordingly, research and development as well as corporate administrative functions are performed within this reportable segment. As of September 30, 2005 and 2004, cost allocations of these functions to Europe Medical have not been performed.

     Manufacturing activities are performed primarily within the U.S. Medical segment. Revenue associated with intersegment product transfers to Europe Medical was $384,000 and $352,000 for the three months ended September 30, 2005 and 2004, respectively, and $1,010,000 and $1,062,000 for the nine months ended September 30, 2005 and 2004, respectively. Revenue is based upon transfer prices, which provide for intersegment profit that is eliminated upon consolidation.

Europe Medical

     The Europe Medical segment is a marketing and sales subsidiary located in The Netherlands that serves Europe as well as the Middle East. Products offered by this reportable segment are the same as those offered by U.S. Medical. The Company has received CE mark approval for products that relate to four applications of excimer laser technology — coronary atherectomy, in-stent restenosis, lead removal, and peripheral atherectomy to clear blockages in leg arteries.

     Summary financial information relating to reportable segment operations is shown below. Intersegment transfers as well as intercompany assets and liabilities are excluded from the information provided (in thousands):

	Three months ended				Nine months ended
	September 30				September 30
Revenue:	2005		2004		2005		2004
U.S. Medical	$	10,123	$	8,169	$	27,409	$	23,271
Europe Medical		1,107		765		3,519		2,107
Total revenue	$	11,230	$	8,934	$	30,928	$	25,378

Page 9

	Three months ended					Nine months ended
	September 30					September 30
Segment net income (loss):	2005		2004			2005		2004
U.S. Medical	$	410	$	519		$	539	$	1,181
Europe Medical		96		(40	)		284		(166	)
Total net income	$	506	$	479		$	823	$	1,015

	September 30,		December 31,
Segment assets:	2005		2004
U.S. Medical	$	34,849	$	29,786
Europe Medical		2,362		3,252
Total assets	$	37,211	$	33,038

(8) Income Taxes

     The Company accounts for income taxes pursuant to Statement of Financial Accounting Standards No. 109, Accounting for Income Taxes, which requires the use of the asset and liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, operating losses and tax credit carryforwards.

     A valuation allowance is required to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.

     In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the projected future taxable income, and tax planning strategies in making this assessment. In 2004, based upon the level of historical income and projections for future income, management determined it is more likely than not a portion of the deferred tax assets will be recoverable.

Page 10

     Income tax expense attributable to income before income taxes consists of the following (in thousands):

	Three months ended				Nine months ended
	September 30,				September 30,
	2005		2004		2005		2004
Current:
Federal	$	—	$	—	$	—	$	—
State		—		21		—		63
Foreign		—		—		—		—
		—		21		—		63
Deferred:
Federal		103		—		509		—
State		14		—		66		—
Foreign		—		—		—		—
		117		—		575		—
Income tax expense	$	117	$	21	$	575	$	63

     The increase in the Company’s effective tax rate is due primarily to the partial recognition of a deferred tax asset at the end of 2004. For the 2004 periods, the Company recorded only a current provision for state taxes. Subsequent to recording the deferred tax asset, the Company has been providing the full amount of income tax expense against current earnings. No further tax benefit has been recognized related to decreases in the valuation allowance against our deferred tax assets during 2005, however, management will continue to assess the realization of the deferred tax asset on a quarterly basis. The effective tax rate as of September 30, 2005 is lower than the rate at June 30, 2005 due to a change in the transfer prices charged to the Company’s Netherlands subsidiary, which had the effect of eliminating losses recognized by that subsidiary which were generating no tax benefit.

     No adjustment to the Company’s valuation allowance against its deferred tax asset as a result of its ongoing quarterly evaluation was made as of September 30, 2005.

(9) Revenue Recognition

     Revenue from the sale of the Company’s disposable products is recognized when products are shipped to the customer and title transfers. Revenue from the sale of excimer laser systems is recognized after completion of contractual obligations, which generally include delivery and installation of the systems and in some cases completion of physician training. The Company’s field service engineers are responsible for installation of each laser and participation in the training program at each site. The Company generally provides a one-year warranty on laser sales, which includes parts, labor and replacement gas. The fair value of this service is deferred and recognized as revenue on a straight-line basis over the related warranty period and warranty costs are expensed in the period they are incurred. Upon expiration of the warranty period, the Company offers similar service to its customers under service contracts or on a fee-for-service basis. Revenue allocated to service contracts is initially recorded as deferred revenue and recognized over the related service contract period, which is generally one year. Revenue from fee-for-service arrangements is recognized upon completion of the related service.

Page 11

     The Company offers three laser system placement programs, which are described below, in addition to the sale of laser systems:

     Evergreen rental program — Rental revenue under this program varies on a sliding scale depending on the customer’s catheter purchases each month. Rental revenue is invoiced on a monthly basis and revenue is recognized upon invoicing. The laser unit is transferred to the equipment held for rental or loan account upon shipment, and depreciation expense is recorded within cost of sales based upon a three- to five-year expected life of the unit. As of September 30, 2005, 56 laser units were in place under the Evergreen program.

     Cap-free rental program — Under this program, the Company retains title to the laser system and the customer agrees to a catheter price list that includes a per-unit surcharge. Customers are expected to make minimum purchases of catheters at regular intervals, and the Company reserves the right to have the unit returned should the minimum purchases not be made. The Company recognizes the total surcharge as rental revenue each month, believing it to be the best measurement of revenue associated with the customers’ use of the laser unit for the month. The laser unit is transferred to the equipment held for rental or loan account upon shipment, and depreciation expense is recorded with cost of sales based upon a three- to five-year expected life of the unit. Costs to maintain the equipment are expensed as incurred. As of September 30, 2005, 20 laser units were in place under the Cap-free program.

     Evaluation programs — The Company “loans” laser systems to institutions for use over a short period of time, usually three to six months. The loan of the equipment is to create awareness of the Company’s products and their capabilities, and no revenue is earned or recognized in connection with the placement of a loaned laser, although sales of disposable products result from the laser placement. The laser unit is transferred to the equipment held for rental or loan account upon shipment, and depreciation expense is recorded within selling, general and administrative expense based upon a three- to five-year expected life of the unit. As of September 30, 2005, 57 laser units were in place under the evaluation program.

(10) Commitments and Contingencies

     The Company has a disagreement with a licensor regarding the level of past royalty payments since inception of a license agreement that was executed in October 2000. The disagreement over past royalty payments centers on the treatment of certain service-based revenue, including repair and maintenance, and physician and clinical training services. Management believes that these are beyond the scope of the license agreement. In August 2004, the licensor commenced arbitration proceedings as provided for under the license agreement. In July 2005, the arbitrator ruled that the Company is required to pay royalties on certain service-based revenue. In September, 2005, we received further clarification of the arbitrator’s ruling and as a result recorded an additional loss provision of $280,000, bringing the total accrued loss provision to approximately $2,454,000 associated with the resolution of this matter, which represents management’s best estimate of costs to resolve the matter as of September 30, 2005.

     On September 24, 2004, the Court of Appeal of Amsterdam rejected an appeal made by the Company on a judgment awarded to an Italian distributor (the Distributor) by the District Court of Amsterdam. The Distributor originally filed suit in July 1999, and the lower court’s judgment was rendered in April 2002. The Court of Appeal of Amsterdam affirmed the lower court’s opinion that an exclusive distributor agreement for the Italian market was entered between the parties for the three-year period ending December 31, 2001, and that the Distributor may exercise its right to compensation from the Company for its loss of profits during such three-year period. The appellate court awarded the Distributor the costs of the appeal and has referred the case back to the lower court for determination of the loss of profits. The Distributor asserts lost profits of approximately $1,500,000, which is based on their estimate of potential profits during the three-year period. The Company estimates that the lost profits to the Distributor for the period, plus estimated interest and awarded court costs, totaled approximately

Page 12

$250,000. Such amount was included in accrued liabilities at September 30, 2005. The Company intends to vigorously defend the calculation of lost profits.

     The Company is involved in various other claims and legal actions arising in the ordinary course of business, which, in the opinion of management, the ultimate disposition of such matters will not have a material adverse effect on the Company’s consolidated financial position, results of operations, or liquidity.

(11) Related Party Transaction

     In February 2005, the Company entered into an agreement with a director of the Company whereby the director agreed to provide training services to outside physicians on behalf of the Company. The total to be paid under the agreement, which expires on December 31, 2005, is $75,000. During the three and nine months ended September 30, 2005, the total amount incurred for training services provided by the director totaled $18,750 and $56,250, respectively.

(12) Reclassifications

     Certain amounts from prior condensed financial statements have been reclassified to conform with the September 30, 2005 presentation.

Item 2. Management’s Discussion and Analysis of Results of Operations and Financial Condition

Forward-Looking Statements

     This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. For a description of such risks and uncertainties, which could cause the actual results, performance or achievements of the Company to be materially different from any anticipated results, performance or achievements, please see the risk factors below. Readers are urged to carefully review and consider the various disclosures made in this report and in our other reports filed with the SEC that attempt to advise interested parties of certain risks and factors that may affect our business. This analysis should be read in conjunction with our consolidated financial statements and related notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Form 10-K, filed on March 31, 2005. Spectranetics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements due to new information or other events.

Corporate Overview

     We develop, manufacture, market and distribute single-use medical devices used in minimally invasive surgical procedures within the vascular system in conjunction with our proprietary excimer laser system. Excimer laser technology delivers comparatively cool ultraviolet energy in short, controlled energy pulses to ablate or remove tissue. Our excimer laser system includes the CVX-300® laser unit and various fiber-optic delivery devices, including disposable catheters and sheaths. Our excimer laser system is the only excimer laser system approved in the United States and Europe for use in multiple, minimally invasive cardiovascular applications. Our excimer laser system is used in complex atherectomy procedures to open clogged or obstructed arteries in the coronary and peripheral vascular system. It is also used to remove lead wires from patients with implanted pacemakers or cardioverter defibrillators, which are electronic devices that regulate the heartbeat. Our laser system is typically used adjunctively with balloon catheters and cardiovascular stents. We compete with alternative technologies including mechanical atherectomy and thrombectomy devices. In April 2004, we obtained 510(k)

Page 13

Item 2. Management’s Discussion and Analysis of Results of Operations and Financial Condition(cont’d)

marketing clearance from the Food and Drug Administration (FDA) for a laser-based treatment of total occlusions (blockages) in the legs not crossable with a guidewire. Some of the patients with total occlusions in the leg suffer from critical limb ischemia (CLI), a debilitating condition that begins with resting leg pain and often leads to tissue loss or amputation as a result of a lack of blood flow to the legs.

     Although 86% of our revenue was derived in the United States for the three months ended September 30, 2005, we also have regulatory approval to market our products in two key international markets. In Europe, we have the required approvals to market our products for the same indications that are approved in the United States. We have also received approval to market certain coronary atherectomy products in Japan, and are seeking additional approvals there for our newer coronary, peripheral and lead removal products. Our distributor, DVx Japan, is assisting us in pursuing reimbursement approval in Japan. We currently expect reimbursement approval in late 2006, although there are no assurances that reimbursement will be received then, if at all. We do not expect significant revenue increases in Japan until reimbursement is received.

     Our strategy is to develop additional applications for our excimer laser system; gather and develop clinical data for publication in peer-reviewed journals; increase utilization of our FDA-approved products; and expand our installed base of laser systems. We will focus our efforts on further penetration of the peripheral market. We intend to do so through continuing expansion of our field sales force, expanded clinical research, and increased product development efforts. We believe these costs are necessary to establish our laser technology within the large, underserved peripheral market and to provide a platform for sustainable revenue growth in future years. As a result of the increased expenses, we may not maintain profitability. Although we believe that net losses, if any, would be temporary as we build our peripheral business, there are no assurances to that effect.

     In 1993, the FDA approved for commercialization our CVX-300 laser system and the first generation of our fiber optic coronary atherectomy catheters. Several improvements and additions to our coronary atherectomy product line have been made since 1993 and have been approved for commercialization by the FDA. In 1997, we secured FDA approval to use our excimer laser system for removal of pacemaker and defibrillator leads, and we secured FDA approval in 2001 to market certain products for use in restenosed (clogged) stents (thin steel mesh tubes used to support the walls of coronary arteries) as a pretreatment prior to brachytherapy (radiation therapy).

     In April 2004, we received 510(k) marketing clearance from the FDA for our CliRpath excimer laser catheters which are indicated for use in the endovascular treatment of symptomatic infrainguinal lower extremity vascular disease when total obstructions are not crossable with a guidewire. The data submitted to the FDA showed that the limb salvage rate (no major amputations) among the 47 patients treated was 95% for those patients surviving six months following the procedure. There was no difference in serious adverse events as compared with the entire set of patients treated in the LACI (Laser Angioplasty for Critical Limb Ischemia) trial.

     We are currently exploring the use of our technology to treat blockages caused by the formation of thrombus (blood clots) and acute myocardial infarction (AMI, or heart attack). The Extended FAMILI trial is a feasibility trial that will benchmark quantitative endpoints common in other AMI trials, such as myocardial blush scores and the reduction in infarct size for the subset of patients. Enrollment in the trial was completed as of June 30, 2005. We expect to complete the six-month follow-up and data analysis in the first quarter of 2006.

     We will be initiating additional clinical research studies during the first quarter of 2006 focused on the treatment of peripheral vascular disease. We also plan to commence with a study for the treatment of chronic total occlusions in the coronary vascular system in 2006.

Page 14

Item 2. Management’s Discussion and Analysis of Results of Operations and Financial Condition(cont’d)

     As to product development, our primary focus is to develop products capable of generating larger lumens within a blocked superficial femoral artery (SFA) which is the main leg artery above the knee. We currently have two products that we believe are capable of generating larger lumens in the SFA. The first product is the 2.5 Turbo catheter. This is a fiber-optic catheter with a larger ablation area, and improved ablation efficiency, which we believe will reduce procedure times. It was submitted to the FDA in a 510(K) application and we received FDA clearance in August 2005. The second larger lumen product, which we currently refer to as the bias sheath, is nearing completion of product development. We are currently in discussions with the FDA to determine the level of clinical data required and the nature of such testing (i.e., clinical endpoints, length of follow-up, etc.). We anticipate that clinical research using the bias sheath product will begin in late 2005 or early 2006.

     We are also in the early stages of product development on various products targeted in the treatment of chronic total occlusions, or CTO’s.

Page 15

Item 2. Management’s Discussion and Analysis of Results of Operations and Financial Condition(cont’d)

Results of Operations

     The following table summarizes key supplemental financial information for the last 5 quarters.

	3rd Qtr			4th Qtr			1st Qtr			2nd Qtr			3rd Qtr
(000’s, except per share and unit sale amounts)
Laser Revenue:
Equipment sales	$	665		$	930		$	416		$	691		$	767
Rental fees		347			335			367			406			447
Total laser revenue		1,012			1,265			783			1,097			1,214
Disposable Products Revenue:
Atherectomy revenue		3,366			3,605			3,373			4,962			5,029
Lead removal revenue		3,213			3,177			3,433			3,368			3,650
Total disposable products revenue		6,579			6,782			6,806			8,330			8,679
Service and other revenue		1,343			1,283			1,464			1,218			1,337
Total revenue		8,934			9,330			9,053			10,645			11,230
Net income	$	479		$	1,937		$	75		$	242		$	506
Net income per share:
Basic	$	0.02		$	0.08		$	0.00		$	0.01		$	0.02
Diluted	$	0.02		$	0.07		$	0.00		$	0.01		$	0.02
Net cash provided by (used in) operating activities	$	(78	)	$	1,069		$	(1,011	)	$	(244	)	$	460
Total cash and investment securities (current and non-current)	$	16,189		$	17,410		$	15,941		$	16,074		$	16,800
Laser sales summary:
Laser sales from inventory		3			3			2			3			4
Laser sales from evaluation/rental units		4			4			1			2			2
Total laser sales		7			7			3			5			6
Worldwide Installed Base Summary:
Laser sales from inventory		3			3			2			3			4
Rental placements		0			1			1			9			14
Evaluation placements		9			15			16			8			4
Laser placements during quarter		12			19			19			20			22
Buy-backs/returns during quarter		(2	)		(6	)		(7	)		(3	)		(4	)
Net laser placements during quarter		10			13			12			17			18
Total lasers placed at end of quarter		404			417			429			446			464

Page 16

Item 2. Management’s Discussion and Analysis of Results of Operations and Financial Condition(cont’d)

Three Months Ended September 30, 2005 Compared with Three Months Ended September 30, 2004

     Revenue for the third quarter of 2005 was $11,230,000, an increase of 26 percent as compared to $8,934,000 during the third quarter of 2004. This increase is mainly attributable to a 32 percent increase in disposable products revenue, which consists of single-use catheter products, and a 20 percent increase in equipment revenue.

     We separate our disposable products revenue into two separate categories — atherectomy and lead removal. For the three months ended September 30, 2005, our atherectomy revenue totaled $5,092,000 (58% of our disposable products revenue) and our lead removal revenue totaled $3,650,000 (42% of our disposable products revenue). For the three months ended September 30, 2004, our atherectomy revenue totaled $3,366,000 (51% of our disposable products revenue) and our lead removal revenue totaled $3,109,000 (47% of our disposable products revenue). Atherectomy revenue, which includes products used in both the coronary and peripheral vascular systems, grew 49% in the third quarter of 2005 as compared with the third quarter of 2004. Atherectomy revenue growth was primarily due to unit volume increases from the continued penetration of our CliRpath product line since its launch in May 2004, following the April 2004 FDA clearance to market these products to treat total occlusions in the legs that are not crossable with a guidewire. Atherectomy revenue growth from current levels will depend on our ability to increase market acceptance of our CliRpath product line and our ability to continue to increase the worldwide installed base of lasers, and future success of our ongoing clinical research and product development within the coronary and peripheral atherectomy markets.

     Lead removal revenue grew 14% for the three-month period ended September 30, 2005, as compared with the same three-month period in 2004. We continue to believe our lead removal revenue is increasing primarily as a result of the increase in the use of implantable cardioverter defibrillators (ICD), devices that regulate heart rhythm. When an ICD is implanted, it often replaces a pacemaker. In these cases, the old pacemaker leads may be removed to minimize venous obstruction when the new ICD leads are implanted. Recent clinical studies (MADIT and ScD-Heft) have expanded the patient population that may benefit from defibrillator implants. The results of the MADIT clinical trial became available in 2003 and ScD-Heft clinical trials were made public in February 2004. Growth in the implantable defibrillator market may accelerate, depending on the establishment of referral patients to electrophysiologists for this expanded patient pool and the additional reimbursement recently established for the hospitals and electrophysiologists for these patients. Generally, growth in the implantable defibrillator market contributes to growth in our lead removal business. Although we expect our lead removal business to continue to grow, there can be no assurances to that effect. The current standard of care in this market is to cap leads and leave them in the body rather than lead removal. We estimate that 95% of replaced pacemaker or defibrillator leads are capped and left in the body. We have initiated programs to examine the costs and frequency of complication associated with abandoned leads, but there are no assurances that these programs will be successful or will change the current standard of care. We expect that these favorable market dynamics will contribute to lead removal revenue growth for the remainder of 2005; however, there can be no assurances this will occur.

Page 17

Item 2. Management’s Discussion and Analysis of Results of Operations and Financial Condition(cont’d)

     Laser equipment revenue was $1,214,000 and $1,012,000 for the three months ended September 30, 2005 and 2004, respectively. Laser sales revenue, which is included in laser equipment revenue, increased to $767,000 during the three month period ended September 30, 2005 from $665,000 during the three month period ended September 30, 2004. We sold 6 laser units (4 as an outright sale from inventory and 2 sale conversions from evaluation or rental programs) during the third quarter of 2005 and 7 laser units (3 as an outright sale from inventory and 4 sale conversions from evaluation or rental programs) during the same quarter in 2004. The increase in laser sales revenue is due to the fact that more sales from inventory occurred in the third quarter of 2005 versus the third quarter of 2004, with such sales occurring primarily outside of the U.S. and yielding a higher sales price than sale conversions under our evaluation or rental programs. Rental revenue increased 29% during the three-month period ended September 30, 2005, from $347,000 in the third quarter of 2004 to $447,000 in the third quarter of 2005. This increase is consistent with the increase in our installed rental base of laser systems.

     Our worldwide installed base of laser systems increased by 18 during the quarter ended September 30, 2005, compared with an increase of 10 laser systems during the same quarter last year. This brings our worldwide installed base of laser systems to 464 (351 in the U.S.) at September 30, 2005.

     Service and other revenue did not change significantly for the third quarter of 2005 as compared to the third quarter of 2004.

     Gross margin remained consistent at 76 percent for both quarters ended September 30, 2005 and 2004.

     Operating expenses of $8,078,000 in the third quarter of 2005 increased 27 percent from $6,368,000 in the third quarter of 2004. This increase is mainly due to a 26 percent increase in research, development and other technology expenses and a 27 percent increase in selling, general and administrative expenses relative to the same period in 2004.

     Selling, general and administrative expenses increased 27 percent to $6,128,000 for the three months ended September 30, 2005 from $4,817,000 in the prior year period. The increase is primarily due to:

• Marketing and selling expenses increased approximately $1,200,000 in the quarter compared with last year’s quarter primarily as a result of the following:

• Increased personnel-related costs of approximately $350,000 associated with the staffing of 10 additional employees within our U.S. clinical sales and training organization in the third quarter of 2005 as compared with the third quarter of 2004. These costs include salaries and related taxes, recruiting, and travel costs.

• Increased commissions of approximately $393,000, which is mainly due to the increase in revenues and additional employees.

• Increased costs of approximately $323,000 associated with increased volume of marketing communications, Company-sponsored educational summits for physicians, and conventions, all in support of the increase in sales.

Page 18

Item 2. Management’s Discussion and Analysis of Results of Operations and Financial Condition(cont’d)

• General and administrative expenses increased approximately $120,000 in the third quarter of 2005 compared with the same period of the prior year, primarily the result of the following:

• Increased costs of approximately $75,000 associated with various legal proceedings discussed in Note 10 to the condensed consolidated financial statements

• In the prior year third quarter, the Company recorded a $39,000 credit to bad debt expense to reflect the collection of certain accounts previously reserved for. No bad debt expense was recorded during the third quarter of 2005, as the Company’s estimate of the collectibility of accounts receivable did not change during the quarter.

     Research, development and other technology expenses of $1,950,000 for the third quarter of 2005 represent an increase of 26 percent from $1,551,000 in the third quarter of 2004. Costs included within research, development and other technology expenses are research and development costs, clinical studies costs and royalty costs associated with various license agreements with third-party licensors. The increase is primarily due to:

• Increased personnel-related costs of $140,000 due primarily to the hiring of 4 additional engineering and clinical studies employees.

• Increased legal fees and other outside services of approximately $115,000 related to the application for patents and annual maintenance of our patent portfolio, and fees associated with the preparation of project agreements.

• Increased royalty expenses of approximately $180,000 due primarily to an additional provision of $280,000 to increase the reserve for the estimated settlement of a royalty dispute as discussed in Note 10 to the condensed consolidated financial statements. This was partially offset by the expiration of certain patents underlying licensed technology and decreased royalty rates for certain other existing license agreements.

• Decreased clinical study costs of approximately $47,000.

     Interest income increased 102 percent in the third quarter of 2005 to $113,000 due to higher yields on the Company’s interest-bearing securities, which consist primarily of cash equivalents, and U.S. Treasury and agency notes. The higher yields are consistent with the overall change in the interest rate environment between the third quarter of 2004 and the third quarter of 2005.

     For the three months ended September 30, 2005, we recorded a provision for income tax expense of $117,000, or 19% of income before income tax expense, compared to income tax expense of $21,000, or 4% of income before income tax expense, for the same period of the prior year. The increase in our effective tax rate is due primarily to the partial recognition of a deferred tax asset at the end of 2004. Subsequent to recording that asset, we are providing the full amount of income tax expense against current earnings. No further tax benefit has been recognized related to decreases in the valuation allowance against our deferred tax assets during 2005, however, we will continue to assess the realization of the deferred tax asset on a quarterly basis. Income tax expense for the third quarter of 2004 represented a current provision for state taxes.

Page 19

Item 2. Management’s Discussion and Analysis of Results of Operations and Financial Condition(cont’d)

     During the third quarter of 2005, we evaluated our transfer pricing policy with our Netherlands subsidiary. As a result of this evaluation, changes to the transfer prices charged to the subsidiary were made which had the effect of eliminating losses incurred by the subsidiary which generated no tax benefit. This had the further effect of reducing our estimated effective year-to-date tax rate from 59% of pretax income at June 30, 2005 to 41% at September 30, 2005, and the effective tax rate for the third quarter of 2005 reflects the lowering of the effective year-to-date rate.

     Net income for the three months ended September 30, 2005 was $506,000, compared with net income of $479,000 in the same quarter last year.

     The functional currency of Spectranetics International B.V. is the euro. All revenue and expenses are translated to U.S. dollars in the consolidated statements of operations using weighted average exchange rates during the period. Fluctuation in euro currency rates during the three months ended September 30, 2005, as compared with the three months ended September 30, 2004, caused an increase in consolidated revenue of $50,000 and an increase in consolidated operating expenses of $42,000.

Nine Months Ended September 30, 2005 Compared with Nine Months Ended September 30, 2004

     Revenue for the nine months ended September 30, 2005 was $30,928,000, an increase of 22 percent from revenue of $25,378,000 for the nine months ended September 30, 2004. This resulted from an increase of 26 percent in disposable products revenue, an increase of 23 percent in equipment revenue and a six percent increase in service and other revenue.

     A 35 percent increase in atherectomy revenue combined with a 17 percent increase in lead removal products revenue resulted in the increase in disposable products revenue. The increase in disposable product revenue was almost entirely due to unit volume increases.

     Atherectomy revenue growth increased significantly due to the continued penetration and market acceptance of our CliRpath product line since its introduction in May 2004. The CLirpath product line consists of catheters used for the treatment of total occlusions in the legs which are not crossable with a guidewire. Atherectomy revenue growth from current levels will depend on our ability to increase market acceptance of our CliRpath product line and our ability to continue to increase the worldwide installed base of lasers, and future success of our ongoing clinical research and product development within the coronary and peripheral atherectomy markets.

     We believe that our lead removal business continues to benefit from the expansion of patients eligible for implantable cardioverter defibrillators (ICD), a device that regulates heart rhythm. When an ICD is implanted, it often replaces a pacemaker. In these cases, the old pacemaker leads may be removed to minimize venous obstruction when the new ICD leads are implanted. We continue to believe that these favorable market dynamics will contribute to lead removal revenue growth for the remainder of 2005; however, there can be no assurances that this will occur.

     Equipment revenue of $3,094,000 during the nine months ended September 30, 2005 increased 23 percent from $2,507,000 for the prior year period. For the nine months ended September 30, 2005, our installed base of excimer laser systems increased by 47 to 464 excimer laser systems (351 in the United States) compared with 21 net placements during the nine months ended September 30, 2004.

     Laser sales revenue, which is included in laser equipment revenue, increased 25% to $1,874,000 for the first nine months of 2005 from $1,501,000 for the same period in 2004. The increase was due to

Page 20

Item 2. Management’s Discussion and Analysis of Results of Operations and Financial Condition(cont’d)

increased average sale prices for the units sold and occurred primarily outside the U.S. Rental revenue increased 21% from $1,006,000 for the nine month period ended September 30, 2004 to $1,220,000 for the nine month period ended September 30, 2005, which was mainly due to an increase in systems placed under our various rental programs, including our cap-free program introduced in the second quarter of 2005.

     Service and other revenue of $4,153,000 during the nine months ended September 30, 2005 increased 6% from $3,914,000 for the nine months ended September 30, 2004, due to the increased number of laser unit placements.

     Gross margin increased to 76 percent during the nine months ended September 30, 2005, from 75 percent for the nine months ended September 30, 2004. This increase was mainly due to manufacturing efficiencies realized as a result of the higher volume of catheters produced and sold.

     Operating expenses increased 24 percent in the nine months ended September 30, 2005 to $22,362,000, compared with $18,044,000 for the nine months ended September 30, 2004.

     Selling, general and administrative expenses increased 21 percent to $17,394,000 for the nine months ended September 30, 2005 from $14,146,000 for the nine months ended September 30, 2004. This increase is primarily due to:

• Marketing and selling expenses increased approximately $2,640,000 compared with last year as a result of the following:

• Approximately $485,000 relates to personnel-related expenses associated with an increase of 10 additional employees in our field sales and training organization this year and $819,000 relates to higher commissions as a result of increased revenue compared with the prior year period.

• Approximately $507,000 relates to additional physician training costs incurred primarily in peer-to-peer clinical training sessions combined with increased convention, meeting and education costs, primarily the result of attendance at an increasing number of tradeshows and conventions.

• Approximately $124,000 relates to increased depreciation costs associated with a higher number of evaluation systems in place during the first nine months of 2005 as compared with the same period in 2004. Refer to the “Liquidity and Capital Resources” section of this report for a further discussion of these programs.

• Approximately $464,000 relates to increased costs of our foreign operations. Of this amount, $350,000 relates to costs associated with the hiring of an additional employee for the European sales organization and for the payment of additional commissions on increased sales for the nine month period ended September 30, 2005 as compared to the same period in 2004. An additional increase of approximately $115,000 is due to increased costs associated with convention attendance and other marketing-related materials.

Page 21

Item 2. Management’s Discussion and Analysis of Results of Operations and Financial Condition(cont’d)

• Approximately $185,000 related to commissions paid to our independent distributor for increased sales made in the Far East.

• An increase of $607,000 in general and administrative expenses from last year is due primarily to the following:

• Increased legal fees of approximately $325,000, primarily due to the legal proceeding associated with the Rentrop and Edwards’ lawsuits. Legal matters are discussed within Part II, Item 1 — Legal Proceedings within this report.

• Increased personnel-related costs of approximately $54,000 associated with increased staffing.

• Increased audit and other fees totaling approximately $173,000, primarily due to an increase in the amounts spent during early 2005 relating to the completion of Sarbanes-Oxley compliance for 2004.

     Research, development and other technology expenses of $4,968,000 for the nine months ended September 30, 2005 increased 27 percent from $3,898,000 for the nine months ended September 30, 2004. Costs included within research, development and other technology expenses are research and development costs, clinical studies costs and royalty costs associated with various license agreements with third-party licensors. The increase is primarily due to the following:

• Increased personnel-related costs of $315,000 due to the hiring of 4 additional engineering employees, and an additional $100,000 of internal labor allocations related to R&D testing.

• Increased legal fees and other outside services of approximately $170,000 related mainly for the application and maintenance of patents and the fees associated with the preparation of project and other agreements.

• Increased materials and other costs of approximately $105,000 due to increased research and development activities during the first nine months of 2005 as compared to the same period in the prior year.

• Increased royalty expenses of approximately $33,000 due primarily to an additional provision of $280,000 to increase the reserve for the estimated settlement of a royalty dispute as discussed in Note 10 to the condensed consolidated financial statements. This was partially offset by the expiration of certain patents underlying licensed technology and decreased royalty rates for certain other existing license agreements.

Page 22

Item 2. Management’s Discussion and Analysis of Results of Operations and Financial Condition(cont’d)

     Interest income for the nine months ended September 30, 2005 was $290,000, compared with $152,000 last year. The increase in interest income in 2005 is mainly due to higher yields on our interest-bearing securities, which consist primarily of cash equivalents, and U.S. Treasury and agency notes.

     For the nine months ended September 30, 2005, we recorded a provision for income tax expense of $575,000, or 41% of income before income tax expense, compared to income tax expense of $63,000, or 7% of income before income tax expense, for the same period of the prior year. The increase in our effective tax rate is due primarily to the partial recognition of a deferred tax asset at the end of 2004. Subsequent to recording that asset, we are providing the full amount of income tax expense against current earnings. No further tax benefit has been recognized related to decreases in the valuation allowance against our deferred tax assets during 2005, however, we will continue to assess the realization of the deferred tax asset on a quarterly basis. For the nine months ended September 30, 2004, prior to the recognition of the deferred tax asset, we recorded only a current provision of $63,000 for state taxes.

     Net income for the nine months ended September 30, 2005, was $823,000, compared with net income of $1,015,000 for the same period in 2004.

     The functional currency of Spectranetics International B.V. is the euro. All revenue and expenses are translated to U.S. dollars in the consolidated statements of operations using weighted average exchange rates during the period. Fluctuation in euro currency rates during the nine months ended September 30, 2005, as compared with the nine months ended September 30, 2004, caused an increase in consolidated revenue of $111,000 and an increase in consolidated operating expenses of $79,000.

Liquidity and Capital Resources

     Cash, cash equivalents, and current and long-term investments in marketable securities as of September 30, 2005 were $16,800,000, a decrease of $610,000 from $17,410,000 at December 31, 2004. The primary reason for the decrease is due to the $1,350,000 purchase of the building and land in March 2005 that houses our manufacturing facilities. In addition, $275,000 was paid to a licensor in February 2005 for back royalties associated with an amendment to the license agreement with the licensor. The payment of the back royalties is discussed in Part II, Item 1 — Legal Proceedings within this report.

     Cash used by operating activities of $795,000 for the nine months ended September 30, 2005 consisted primarily of the following:

• Increased inventories of $1,680,000, primarily the result of higher stocking levels to meet the increase in laser and catheter demand.

• Increase in equipment held for rental or loan of $1,914,000 as a result of expanding placement activity of our laser systems through evaluation, “cap free,” or rental programs.

• Increase in accounts receivable of approximately $960,000 due to increased sales.

     The above uses of cash by operating activities were offset by the following sources for the nine months ended September 30, 2005:

• Net income of $823,000 for the nine months ended September 30, 2005, plus non-cash expenses of $1,849,000, which consist of depreciation and amortization of $1,267,000, the fair value of options granted for consulting services of $10,000, and the recognition of deferred taxes of $572,000.

Page 23

Item 2. Management’s Discussion and Analysis of Results of Operations and Financial Condition(cont’d)

• An increase in accounts payable and accrued liabilities of $988,000, mainly due to increased European commission accruals as a result of higher revenues, as well as increased trade accounts payable as a result of increased purchasing activity.

     The table below presents the change in receivables and inventory in relative terms, through the presentation of financial ratios. Days sales outstanding are calculated by dividing the ending accounts receivable balance, net of reserves for sales returns and doubtful accounts, by the average daily sales for the third quarter. Inventory turns are calculated by dividing annualized cost of sales for the third quarter by ending inventory.

	September 30, 2005		December 31, 2004
Days Sales Outstanding		59		61
Inventory Turns		3.1		4.9

     The reduction in inventory turns is primarily due to the increase in inventory as of September 30, 2005 that was necessitated in order to meet the increased demand for our laser systems.

     For the nine months ended September 30, 2005, cash used in investing activities was $264,000, primarily due to the net proceeds of $1,904,000 from the sale of investment securities partially offset by the purchase of the building and land that houses our manufacturing facilities for $1,350,000 and other capital expenditures of $818,000, primarily for additional manufacturing equipment and lease hold improvements.

     Cash provided by financing activities for the nine month period ended September 30, 2005 was $2,489,000, comprised entirely of proceeds from the sale of common stock to employees and former employees as a result of exercises of stock options and stock issuances under our employee stock purchase plan. At September 30, 2005, there was no debt or capital lease obligations.

     At September 30, 2005, and December 31, 2004, we had placed a number of laser systems on rental, “Cap-free,” and loan programs. A total of $8,445,000 and $7,064,000 was recorded as equipment held for rental or loan at September 30, 2005 and December 31, 2004, respectively, and is being depreciated over three to five years, depending on whether the laser system is new or manufactured. The net book value of this equipment was $4,619,000 and $3,681,000 at September 30, 2005 and December 31, 2004, respectively.

     We currently offer three laser system placement programs in addition to the sale of laser systems:

(1)

Evergreen rental program — Rental revenue under this program varies on a sliding scale depending on the customer’s catheter purchases each month. Rental revenue is invoiced on a monthly basis and revenue is recognized upon invoicing. The laser unit is transferred to the equipment held for rental or loan account upon shipment, and depreciation expense is recorded within cost of sales based upon a three- to five-year expected life of the unit. We also offer a straight monthly rental program and there are a small number of hospitals that pay $3000-$5000 per month under this program. As of September 30, 2005, 56 laser units were in place under the rental programs.

(2)

Cap-free rental program — Under this program, we retain title to the laser system and the customer agrees to a catheter price list that includes a per-unit surcharge. Customers are expected to make minimum purchases of catheters at regular intervals, and we reserve the right to have the unit returned should the minimum purchases not be made. We

Page 24

Item 2. Management’s Discussion and Analysis of Results of Operations and Financial Condition(cont’d)

recognize the total surcharge as rental revenue each month, believing it to be the best measurement of revenue associated with the customers’ use of the laser unit each month. The laser unit is transferred to the equipment held for rental or loan account upon shipment, and the depreciation expense related to the system is included in cost of revenue based upon a three- to five-year expected life of the unit. Costs to maintain the equipment are expensed as incurred. As of September 30, 2005, 15 laser units were in place under the Cap-free program.

(3) Evaluation programs — We “loan” laser systems to institutions for use over a short period of time, usually three to six months. The loan of the equipment is to create awareness of our products and their capabilities, and no revenue is earned or recognized in connection with the placement of a loaned laser, although sales of disposable products result from the laser placement. The laser unit is transferred to the equipment held for rental or loan account upon shipment, and depreciation expense is recorded within selling, general and administrative expense based on a three- to five-year expected life of the unit. As of September 30, 2005, 90 laser units were in place under the evaluation program. These laser systems contribute to revenue immediately through the sales of disposable products to customers that have acquired a laser system under an evaluation program. During the nine months ended September 30, 2005 and 2004, five customers and seven customers, respectively, elected to purchase their evaluation laser systems, which accounted for a total of $392,000 and $723,000 of equipment revenue, respectively.

     We believe our liquidity and capital resources as of September 30, 2005 are sufficient to meet our operating and capital requirements through at least the next 12 months. In the event we need additional financing for the operation of our business, we will consider additional public or private financing. Factors influencing the availability of additional financing include our progress in our current clinical trials, investor perception of our prospects and the general condition of the financial markets. We cannot assure you that our existing cash and cash equivalents will be adequate or that additional financing will be available when needed or that, if available, this financing will be obtained on terms favorable to our shareholders or us.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

     We prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America. As such, we are required to make certain estimates, judgments and assumptions that we believe are reasonable based upon the information available. These estimates and assumptions affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. Significant items subject to estimates and assumptions include the carrying amount of property and equipment, intangible assets, valuation allowances for receivables, inventories, and deferred income tax assets; and accrued warranty and royalty expenses. Actual results could differ from those estimates.

     Our critical accounting policies and estimates are included in our Form 10-K, filed with the SEC on March 31, 2005.

Page 25

Item 2. Management’s Discussion and Analysis of Results of Operations and Financial Condition(cont’d)

New Accounting Pronouncements

     In December 2004, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 123 (revised 2004), Share-Based Payments (“Statement 123R”). Statement 123R, which is a revision of Statement 123 and supersedes APB Opinion No. 25, establishes standards for the accounting for transactions in which an entity exchanges its equity instruments for goods or services, primarily focusing on transactions in which an entity obtains employee services. Statement 123R also requires companies to measure the cost of employee services received in exchange for an award of equity instruments (such as stock options and restricted stock) based on the grant-date fair value of the award, and to recognize that cost over the period during which the employee is required to provide service (usually the vesting period of the award). Statement 123R also requires companies to measure the cost of employee services received in exchange for an award of liability instruments (such as stock appreciation rights) based on the current fair value of the award, and to remeasure the fair value of the award at each reporting date.

     Public companies are required to adopt Statement 123R as of the beginning of the first interim period that begins after December 15, 2005 (extended from the previous date of September 15, 2005). The provisions of Statement 123R will affect our accounting for all awards granted, modified, repurchased or cancelled after January 1, 2006. Our accounting for awards granted, but not vested, prior to January 1, 2006 will also be impacted. The provisions of Statement 123R allow companies to adopt the standard on a prospective basis or to restate all periods for which Statement 123 was effective. We expect to adopt Statement 123R on a prospective basis, and our financial statements for periods that begin after December 15, 2005 will include pro forma information as though the standard had been adopted for all periods presented.

     While we have not yet fully quantified the impact of adopting Statement 123R, we believe that such adoption could have a significant impact on our operating income and net earnings in the future. For the three months and nine months ended September 30, 2005, pro forma compensation expense, net of tax, related to equity instruments was $363,000 and $693,000, respectively. Pro forma compensation expense, net of tax, related to equity instruments was $123,000 and $410,000, respectively, for the three and nine months ended September 30, 2004. These amounts were disclosed, but not recorded, in the financial statements for the three and nine months ended September 30, 2005 and 2004.

RISK FACTORS

     We Have a History of Losses and May Not Be Able to Maintain Profitability. We incurred losses from operations since our inception in September 1984 until the second quarter of 2001, and we incurred net losses in the first and second quarters of 2002. At September 30, 2005, we had accumulated $72.6 million in net losses since inception. We expect that our research, development and clinical trial activities and regulatory approvals, together with future selling, general and administrative activities and the costs associated with launching our products for additional indications will result in significant expenses for the foreseeable future. In addition, we expect the adoption of Statement 123R for periods that begin after December 15, 2005 will result in significant compensation expense in future periods. Although we have demonstrated profitability for 13 consecutive quarters, no assurance can be given that we will be able to maintain profitability in the future.

     Increases in our Stock Price are Largely Dependent on our Ability to Grow Revenues. Revenue growth from current levels depends largely on our ability to successfully penetrate the peripheral atherectomy market with our CliRpath product line that was introduced in 2004 and that is targeted at total occlusions (blockages) in the legs. The success of this launch will require increased re-order rates

Page 26

Item 2. Management’s Discussion and Analysis of Results of Operations and Financial Condition(cont’d)

from existing customers and adoption by new customers. Beyond the initial CliRpath product line launch, new products will need to be developed and FDA-approved to sustain revenue growth within the peripheral market. Additional clinical data and new products to treat coronary artery disease will likely be necessary to grow revenue within the coronary market.

     Regulatory Compliance Is Expensive and Can Often Be Denied or Significantly Delayed. The industry in which we compete is subject to extensive regulation by the FDA and comparable state and foreign agencies. Complying with these regulations is costly and time consuming. International regulatory approval processes may take longer than the FDA approval process. If we fail to comply with applicable regulatory requirements, we may be subject to fines, suspensions or revocations of approvals, seizures or recalls of products, operating restrictions, criminal prosecutions and other penalties. We may be unable to obtain future regulatory approval in a timely manner, or at all, if existing regulations are changed or new regulations are adopted. For example, the FDA approval process for the use of excimer laser technology in clearing blocked arteries in the leg took longer than we anticipated due to requests for additional clinical data and changes in regulatory requirements.

     Failures in Clinical Trials May Hurt Our Business and Our Stock Price. All of Spectranetics’ potential products are subject to extensive regulation and will require approval from the FDA and other regulatory agencies prior to commercial sale. The results from pre-clinical testing and early clinical trials may not be predictive of results obtained in large clinical trials. Companies in the medical device industry have suffered significant setbacks in various stages of clinical trials, even in advanced clinical trials, after apparently promising results had been obtained in earlier trials.

     The development of safe and effective products is uncertain and subject to numerous risks. The product development process may take several years, depending on the type, complexity, novelty and intended use of the product. Larger competitors are able to offer larger financial incentives to their customers to support their clinical trials. Enrollment in our clinical trials may be adversely affected by clinical trials financed by our larger competitors. Product candidates that may appear to be promising in development may not reach the market for a number of reasons.

     Product candidates may:

• be found ineffective;

• take longer to progress through clinical trials than had been anticipated; or

• require additional clinical data and testing.

     Our Small Sales and Marketing Team May Be Unable To Compete With Our Larger Competitors or To Reach All Potential Customers. Many of our competitors have larger sales and marketing operations than we do. This allows those competitors to spend more time with potential customers and to focus on a larger number of potential customers, which gives them a significant advantage over our team in making sales. Additionally, our field service organization consists primarily of individuals with extensive clinical experience within hospital catheterization labs; however, their sales experience is limited. We are providing sales training and, as we add new field sales employees, will attempt to recruit candidates with more sales experience. However, there are no assurances that our sales training and recruiting will improve productivity within our field sales organization. Further, there may be more turnover within the field sales organization relative to past history as a result of our transition towards a higher level of sales skills.

     Our Products May Not Achieve Market Acceptance. Excimer laser technology is generally used adjunctively with more established therapies for restoring circulation to clogged or obstructed arteries

Page 27

Item 2. Management’s Discussion and Analysis of Results of Operations and Financial Condition(cont’d)

such as balloon angioplasty and stent implantation. Market acceptance of the excimer laser system depends on our ability to provide incremental clinical and economic data that shows the clinical efficacy and cost effectiveness of, and patient benefits from, excimer laser atherectomy used with balloon angioplasty and stent implantation.

     We May Be Unable To Compete Successfully With Bigger Companies in Our Highly Competitive Industry. Our primary competitors are manufacturers of products used in competing therapies within the coronary and peripheral atherectomy markets, such as:

• bypass surgery (coronary and peripheral);

• atherectomy and thrombectomy, using mechanical methods to remove arterial blockages (coronary and peripheral);

• amputation (peripheral); and

• balloon angioplasty (peripheral).

     We also compete with companies marketing lead extraction devices or removal methods, such as mechanical sheaths. In the lead removal market, we compete worldwide with lead removal devices manufactured by Cook Vascular, Inc. and we compete in Europe with devices manufactured by VascoMed. We believe we are the lead removal market leader and are focusing our efforts on growing the market for the removal of pacemaker and defibrillator leads.

     Although balloon angioplasty and stents are used extensively in the coronary vascular system, we do not compete directly with these products. Rather, our laser technology is most often used as an adjunctive treatment to balloon angioplasty and stents.

     Almost all of our competitors have substantially greater financial, manufacturing, marketing and technical resources than we do. Larger competitors have a broader product line, which enables them to offer customers bundled purchase contracts and quantity discounts. We expect competition to intensify.

     We believe that the primary competitive factors in the interventional cardiovascular market are:

• the ability to treat a variety of lesions safely and effectively;

• the impact of managed care practices, related reimbursement to the health care provider, and procedure costs;

• ease of use;

• size and effectiveness of sales forces; and

• research and development capabilities.

     Manufacturers of atherectomy or thrombectomy devices include Boston Scientific, Guidant, Possis Medical, Inc., Fox Hollow Technologies and Intraluminal Therapeutics.

     Laser placement is a barrier to accessing patient cases for which our disposable products may be suited. Many competing products do not require an up-front investment in the form of a capital equipment purchase, lease, or rental.

     Failure of Third Parties To Reimburse Medical Providers for Our Products May Reduce Our Sales. We sell our CVX-300 laser unit primarily to hospitals, which then bill third-party payers such as government programs and private insurance plans, for the services the hospitals provide using the CVX-300 laser unit. Unlike balloon angioplasty or other atherectomy devices, laser atherectomy requires the acquisition of capital equipment. In some circumstances, the amount reimbursed to a hospital for

Page 28

Item 2. Management’s Discussion and Analysis of Results of Operations and Financial Condition(cont’d)

procedures involving our products may not be adequate to cover a hospital’s costs. We do not believe that reimbursement has materially adversely affected our business to date, but continued cost containment measures by third-party payers could hurt our business in the future.

     In addition, the FDA has required that the label for our coronary products states that adjunctive balloon angioplasty was performed together with laser atherectomy in most of the procedures we submitted to the FDA for pre-market approval. Adjunctive balloon angioplasty requires the purchase of a balloon catheter in addition to the laser catheter. While all approved procedures using the excimer laser system are reimbursable, some third-party payers attempt to deny reimbursement for procedures they believe are duplicative, such as adjunctive balloon angioplasty performed together with laser atherectomy. Third-party payers may also attempt to deny reimbursement if they determine that a device used in a procedure was experimental, was used for a non-approved indication, or was not used in accordance with established pay protocols regarding cost-effective treatment methods. Hospitals that have experienced reimbursement problems or expect to experience reimbursement problems may not purchase our excimer laser systems.

     Technological Change May Result in Our Products Becoming Obsolete. We derive substantially all of our revenue from the sale or lease of the CVX-300 laser unit, related disposable devices and service. Technological progress or new developments in our industry could adversely affect sales of our products. Many companies, some of which have substantially greater resources than we do, are engaged in research and development for the treatment and prevention of coronary artery disease and peripheral vascular disease. These include pharmaceutical approaches as well as development of new or improved angioplasty, atherectomy, thrombectomy or other devices. Our products could be rendered obsolete as a result of future innovations in the treatment of vascular disease.

     Our European Operations May Not Be Successful or May Not Be Able To Achieve Revenue Growth. We utilize distributors throughout most of Europe. The sales and marketing efforts on our behalf by distributors in Europe could fail to attain long-term success.

     We Are Exposed to the Problems That Come From Having International Operations. For the three and nine months ended September 30, 2005, our revenue from international operations represented 14 and 15 percent, respectively, of consolidated revenue. Changes in overseas economic conditions, war, currency exchange rates, foreign tax laws or tariffs or other trade regulations could adversely affect our ability to market our products in these and other countries. The new product approval process in foreign countries is often complex and lengthy. For example, the reimbursement approval process in Japan has taken longer than anticipated due to the complexity of this process. As we expand our international operations, we expect our sales and expenses denominated in foreign currencies to expand. We currently do not hedge against foreign currency fluctuations, which could result in reduced consolidated revenues or increased operating expenses.

     We Have Important Sole Source Suppliers and May Be Unable To Replace Them if They Stop Supplying Us. We purchase certain components of our CVX-300 laser unit from several sole source suppliers. We do not have guaranteed commitments from these suppliers and order products through purchase orders placed with these suppliers from time to time. While we believe that we could obtain replacement components from alternative suppliers, we may be unable to do so.

     Potential Product Liability Claims and Insufficient Insurance Coverage May Hurt Our Business and Stock Price. We are subject to risk of product liability claims. We maintain product liability insurance with coverage and aggregate maximum amounts of $5,000,000. The coverage limits of our insurance policies may be inadequate, and insurance coverage with acceptable terms could be unavailable in the future.

Page 29

Item 2. Management’s Discussion and Analysis of Results of Operations and Financial Condition(cont’d)

     Our Patents and Proprietary Rights May Be Proved Invalid, Which Would Enable Competitors To Copy Our Products; We May Infringe Other Companies’ Rights. We hold patents and licenses to use patented technology, and have patent applications pending. Any patents we have applied for may not be granted. In addition, our patents may not be sufficiently broad to protect our technology or to give us any competitive advantage. Our patents could be challenged as invalid or circumvented by competitors. In addition, the laws of certain foreign countries do not protect our intellectual property rights to the same extent as do the laws of the United States. We do not have patents in many foreign countries. We could be adversely affected if any of our licensors terminate our licenses to use patented technology.

     There may be patents and patent applications owned by others relating to laser and fiber-optic technologies, which, if determined to be valid and enforceable, may be infringed by Spectranetics. Holders of certain patents, including holders of patents involving the use of lasers in the body, may contact us and request that we enter into license agreements for the underlying technology. For example, we have been made aware of a patent issued to Dr. Peter Rentrop for a certain catheter with a diameter of less than 0.9 millimeters and are currently involved in litigation regarding this patent. See Part II, Item 1 — Legal Proceedings herein for further discussion of this litigation. We cannot guarantee a patent holder will not file a lawsuit against us and prevail. If we decide that we need to license technology, we may be unable to obtain these licenses on favorable terms or at all. We may not be able to develop or otherwise obtain alternative technology.

     Litigation concerning patents and proprietary rights is time-consuming, expensive, unpredictable and could divert the efforts of our management. An adverse ruling could subject us to significant liability, require us to seek licenses and restrict our ability to manufacture and sell our products.

     Our Stock Price May Continue To Be Volatile. The market price of our common stock, similar to other small-cap medical device companies, has been, and is likely to continue to be, highly volatile. The following factors may significantly affect the market price of our common stock:

• fluctuations in operating results;

• announcements of technological innovations or new products by Spectranetics or our competitors;

• governmental regulation;

• developments with respect to patents or proprietary rights;

• public concern regarding the safety of products developed by Spectranetics or others;

• the initiation or cessation in coverage of our common stock, or changes in ratings of our common stock, by securities analysts;

• past or future management changes;

• litigation;

• general market conditions; and

• financing of future operations through additional issuances of equity securities, which may result in dilution to existing stockholders and falling stock prices.

     Protections Against Unsolicited Takeovers in Our Rights Plan, Charter and Bylaws May Reduce or Eliminate Our Stockholders’ Ability To Resell Their Shares at a Premium Over Market Price. We have a stockholders’ rights plan that may prevent an unsolicited change of control of Spectranetics. The rights plan may adversely affect the market price of our common stock or the ability of stockholders to participate in a transaction in which they might otherwise receive a premium for their shares. Under the rights plan, rights to purchase preferred stock in certain circumstances have been issued to holders of outstanding shares of common stock, and rights will be issued in the future for any newly issued common

Page 30

Item 2. Management’s Discussion and Analysis of Results of Operations and Financial Condition(cont’d)

stock. Holders of the preferred stock are entitled to certain dividend, voting and liquidation rights that could make it more difficult for a third party to acquire Spectranetics. No preferred stock has been issued under the stockholders’ rights plan.

     Our charter and bylaws contain provisions relating to issuance of preferred stock, special meetings of stockholders and amendments of the bylaws that could have the effect of delaying, deferring or preventing an unsolicited change in the control of Spectranetics. Our Board of Directors is elected for staggered three-year terms, which prevents stockholders from electing all directors at each annual meeting and may have the effect of delaying or deferring a change in control.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

     We are exposed to a variety of risks, including changes in interest rates affecting the return on our investments and foreign currency fluctuations. Our exposure to market rate risk for changes in interest rates relate primarily to our investment portfolio. We attempt to place our investments with high quality issuers and, by policy, limit the amount of credit exposure to any one issuer and do not use derivative financial instruments in our investment portfolio. We maintain an investment portfolio of various issuers, types and maturities, which consist of both fixed and variable rate financial instruments. Marketable securities are classified as available-for-sale, and consequently, are recorded on the balance sheet at fair value with unrealized gains or losses reported as a separate component in stockholders’ equity, net of applicable taxes. At any time, sharp changes in interest rates can affect the value of our investment portfolio and its interest earnings. Currently, we do not hedge these interest rate exposures. Since our investment securities have maturities that are generally less than one year and never more than two years, we do not expect interest rate fluctuations to have a significant impact on the fair value of our investment securities. As of September 30, 2005, the unrealized loss on our investment securities was approximately $91,000.

     As of September 30, 2005, we had cash and cash equivalents of $5.3 million, and current and long-term investment securities of $11.5 million. Overall average duration to maturity for all cash and investment securities is less than one year with 74% of the portfolio under one year and the remaining 26% between one and two years. At September 30, 2005, the investment securities consisted of government or government agency securities.

     Our exposure to foreign currency fluctuations is primarily related to sales of our products in Europe, which are denominated in the euro. Changes in the exchange rate between the euro and the U. S. dollar could adversely affect our revenue and net income. Exposure to foreign currency exchange rate risk may increase over time as our business evolves and our products continue to be introduced into international markets. Currently, we do not hedge against any foreign currencies and, as a result, could incur unanticipated gains or losses. For the quarter ended September 30, 2005, and 2004, approximately $2,000 and $40,000, respectively, of increased revenue and $3,000 and $37,000, respectively, of increased operating expenses were the result of exchange rate fluctuations of the U.S. dollar in relation to the euro. For the nine months ended September 30, 2005, and 2004, approximately $115,000 and $147,000, respectively, of increased revenue and $83,000 and $150,000, respectively, of increased operating expenses were the result of these exchange rate fluctuations. Accordingly, the net impact of exchange rate fluctuations on consolidated net income for the three months ended September 30, 2005 and 2004 was a decrease in net income of $30,000 in 2005 and an increase in 2004 of $3,000. The net exchange rate impact for the nine months ended September 30, 2005 and 2004 the effect on net income was $42,000 and ($3,000), respectively.

Page 31

Item 4. Controls and Procedures

     We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

     As required by SEC Rule 13a-15(b), we carried out an evaluation, under the supervision of and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the quarter covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

     There has been no change in our internal controls over financial reporting during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

Part II—OTHER INFORMATION

Item 1. Legal Proceedings

     In July, 2003, Spectranetics filed a complaint in the United States District Court for the District of Colorado against Dr. Peter Rentrop, which Spectranetics amended in September, 2003, seeking declaratory relief that (1) Spectranetics’ products do not infringe any claims of Dr. Rentrop’s United States Patent No. 6,440,125 (the “‘125 patent”); (2) the claims of the ‘125 patent are invalid and unenforceable; and (3) in the event that the Court finds that the claims of the patent to be valid and enforceable, that Spectranetics is, through its employees, a joint owner of any invention claimed in the ‘125 patent. Spectranetics also brought claims against Dr. Rentrop for damages based upon Dr. Rentrop’s (1) misappropriation of Spectranetics’ trade secrets; (2) breach of the parties’ Confidentiality Agreement; and (3) wrongful taking of Spectranetics’ confidential and proprietary information.

     On January 6, 2004, the United States Patent and Trademark Office issued to Dr Rentrop a continuation patent to the ‘125 patent, United States Patent No. 6,673,064 (the “‘064 patent”). On the same day, Dr. Rentrop filed in the United States District Court for the Southern District of New York, a complaint for patent infringement against Spectranetics, under the ‘064 patent (the “New York case”).

     On January 26, 2004, the Court in Colorado granted Dr. Rentrop’s Motion to Dismiss the Amended Complaint on the basis that the Court lacked personal jurisdiction over Dr. Rentrop, a resident of New York. Spectranetics decided to forgo appealing that decision, thus, there no longer is any case pending in Colorado.

     On March 9, 2004, Spectranetics filed its Answer, Affirmative Defenses and Counterclaims against Dr. Rentrop in the New York case. Spectranetics’ claim is that, in connection with consultation services provided to Spectranetics by Dr. Rentrop, Spectranetics provided Dr. Rentrop with confidential and proprietary information concerning certain of Spectranetics’ laser catheter technology. Spectranetics

Page 32

claims that rather than keeping such information confidential as required by agreement with Spectranetics, Dr. Rentrop used the information to file patent applications associated with the ‘125 and ‘064 patents, which incorporate and claim inventions to which Spectranetics’ personnel contributed significantly and materially, if not exclusively, thus entitling Spectranetics’ personnel to designation at least as co-inventors. Spectranetics also seeks declaratory judgments of non-infringement, invalidity and unenforceability of the patents-in-suit, and has alleged counterclaims against Dr. Rentrop for breach of confidentiality agreement, misappropriation of trade secrets, and conversion.

     The discovery phase of this case is complete. In September 2005, Dr. Rentrop and Spectranetics agreed to mediation hearings which are expected to take place in the first quarter of 2006. There is no assurance that the parties will resolve the dispute during the mediation process. If no resolution is achieved in the case, it will go back to the federal district court in New York.

     On September 24, 2004, the Court of Appeal of Amsterdam rejected an appeal made by Spectranetics International, B.V. (Spectranetics BV), on a judgment awarded to Cardiomedica S.p.A. (Cardiomedica), an Italian company, by the District Court of Amsterdam. Cardiomedica originally filed the suit in July 1999, and the lower court’s judgment was rendered on April 3, 2002. The Court of Appeal of Amsterdam affirmed the lower court’s opinion that an exclusive distributor agreement for the Italian market was entered into between the parties for the three-year period ending December 31, 2001, and that Cardiomedica may exercise its right to compensation from Spectranetics BV for its loss of profits during such three-year period. The appellate court awarded Cardiomedica the costs of the appeal, which approximated $20,000, and has referred the case back to the lower court for determination of the loss of profits. Cardiomedica asserts lost profits of approximately $1,500,000, which is based on their estimate of potential profits during the three-year period. Spectranetics BV estimates that the lost profits to Cardiomedica for the period, plus estimated interest and awarded court costs, totaled $250,000 for the three-year period, and such amount is included in accrued liabilities at September 30, 2005. We intend to vigorously defend the calculation of lost profits.

     Spectranetics has a disagreement with Edwards LifeSciences regarding the level of past royalty payments since inception of a license agreement that was executed in October 2000. The disagreement over past royalty payments centers on the treatment of certain service-based revenue, including repair and maintenance, and physician and clinical training services. We believe that these are beyond the scope of the license agreement. In August 2004, the licensor commenced arbitration proceedings as provided for under the license agreement, and the arbitrator ruled in July 2005 that royalties were due on certain service-based revenue. In September 2005, we received further clarification of the arbitrator’s ruling and as a result recorded an additional loss provision of $280,000, bringing the total accrued loss provision to approximately $2,454,000 associated with the resolution of this matter as of September 30, 2005, which represents management’s best estimate of costs to resolve the matter.

     The Company is involved in other legal proceedings in the normal course of business and does not expect them to have a material adverse effect on our business.

Items 2-5. Not applicable

Page 33

Item 6. Exhibits

10.38	Employment letter agreement between the Company and Will McGuire dated September 14, 2005
31.1(a)	Rule 13(a)-14(a)/15d-14(a) Certification.
31.1(b)	Rule 13(a)-14(a)/15d-14(a) Certification.
32.1(a)	Section 1350 Certification.
32.1(b)	Section 1350 Certification

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	The Spectranetics Corporation (Registrant)
November 9, 2005	/s/ John G. Schulte
	John G. Schulte
	President and Chief Executive Officer
November 9, 2005	/s/ Guy A. Childs
	Guy A. Childs
	Vice President Finance, Chief Financial Officer

Page 34

EXHIBIT INDEX

Exhibit
Number	Description
10.38	Employment letter agreement between the Company and Will McGuire dated September 14, 2005
31.1(a)	Rule 13(a)-14(a)/15d-14(a) Certification.
31.1(b)	Rule 13(a)-14(a)/15d-14(a) Certification.
32.1(a)	Section 1350 Certification.
32.1(b)	Section 1350 Certification